----item----
version: 1
id: {979C14CF-CB85-4AA0-964F-7A4F37BCD37A}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/22/US Capitol Capsule Improving The Biosimilars Review Process Whats Needed
parent: {DB7AFD0C-FF3A-4A4A-B0E2-6A1121FFD09B}
name: US Capitol Capsule Improving The Biosimilars Review Process Whats Needed
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 5d3976ba-1c55-40de-a1ad-666f1e67380e

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{B2967A9C-ABDA-4628-A672-9EDDCD142AEA}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 76

US Capitol Capsule: Improving The Biosimilars Review Process: What's Needed?
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 72

US Capitol Capsule Improving The Biosimilars Review Process Whats Needed
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 14469

<p>As the FDA gets ready to embark on the reauthorization process for the next round of the <i>Biosimilar User Fee Act </i>(BsUFA), which permits the agency to collect user fees from industry to aid in the reviews of biosimilars applications, known as 351(k)s, it wants to hear stakeholders' thoughts at a Dec. 18 public meeting on how well regulators are completing their program goals so far and what should be retained, changed or discontinued to improve performance.</p><p>An interim analysis of the first two-and-a-half years of the first round of BsUFA, which found the FDA spent $65.9m on biosimilars-related work during that period, may shed some light on the agency's ability to handle the workload and costs associated with the reviews of 351(k)s, although the report only examines five applications &ndash; a number that is expected to substantially increase in the next few years.</p><p>Indeed, at a Sept. 17 Senate subcommittee <a href="http://www.scripintelligence.com/home/Woodcock-FDA-Focused-On-Biosimilars-Science-Before-Policy-360510" target="_new">hearing</a>, Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, pointed out that as of July 31, there were 57 "proposed" biosimilars referenced on 16 different innovator biologics enrolled in the agency's Biosimilar Product Development (BPD) program, which was created as a part of BsUFA to provide a mechanism and structure for collecting the development-phase user fees.</p><p>And, Woodcock said, there were "27 other groups that have come and talked to us about developing individual products," but have not yet joined the BPD program.</p><p>Eastern Research Group, Inc. (ERG) of Lexington, Mass., which conducted the independent analysis &ndash; a requirement of the 2012 BsUFA legislation &ndash; noted it originally was contracted to estimate the volume and full cost associated with the FDA's reviews of 351(k)s through the end of fiscal year 2014. </p><p>But because the agency had received only two biosimilars applications by that date, the scope of the analysis was expanded to add the first half of FY 2015, in which three more 351(k)s were received by the FDA. </p><p>Only one of those applications &ndash;Novartis unit Sandoz's <a href="http://www.scripintelligence.com/home/NovartisSandoz-make-history-with-1st-US-biosimilar-Zarxio-357116" target="_new">Zarxio</a> (filgrastim-sndz), which was referenced on Amgen's human granulocyte colony-stimulating factor Neupogen (filgrastim) &ndash; has been approved so far.</p><p>So it's likely companies have been poring over the <a href="http://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125553Orig1s000TOC.cfm" target="_new">documents</a> posted on the FDA's website about the Zarxio review for any insights and lessons learned they may offer firms seeking their own approvals, although one application is not much to go on.</p><p>The 351(k) applications that are known to be pending at the FDA are for biosimilars of pegfilgrastim from Apotex, referenced on Amgen's Neulasta; epoetin alfa from Hospira, referenced on Amgen's Epogen; and infliximab from Celltrion, referenced on Johnson & Johnson unit Janssen's Remicade.</p><p>While the BsUFA program is similar in many ways to the one under the <i>Prescription Drug User Fee Act</i>, which is in the <a href="http://www.scripintelligence.com/home/Senate-chance-to-improve-Cures-but-dont-expect-soon-359643" target="_new">early stages of negotiations</a> for its sixth round, there are differences.</p><p>Specifically, because biosimilars market in the U.S. is still a budding industry, companies engaged in pursuing the FDA's approval are required to pay fees for <a href="http://www.scripintelligence.com/home/comment/Are-FDA-pre-filing-user-fees-in-pharmas-future-359518" target="_new">products in the development phase</a> to generate revenue to support the agency's review work during that stage and enable firms to have meetings with regulators early on in the development process. </p><p>Among the activities on which the FDA is permitted to spend the biosimilar user fees are application and supplement reviews, action letters, facility inspections, monitoring research, postmarketing safety activities and developing and using adverse-event data-collection systems and improved analytical tools. </p><p>While the FDA did not receive any 351(k)s or supplements in FY 2013, the ERG found that the agency devoted "considerable resources" and effort in reviewing submissions for biosimilars in development, meeting with companies to discuss their development programs and developing other "non-application" review portions of the program, such as guidance documents and training staff.</p><p>In fact, ERG said, of the $65.9m the FDA spent in the first 2.5 fiscal years, $23.6m of that was used in FY 2013, with $21.4m expended in FY 2014 and $20.9m used up in the first two quarters of FY 2015.</p><p>ERG said $33.6m of the total funds was spent on labor, while $19.6m went towards operating costs, with the remainder used for "centrally managed account costs."</p><p>In breaking down the costs in hours and full-time equivalents (FTEs), ERG said the FDA's biosimilars review program required 210.8 FTEs over the first 2.5 fiscal years &ndash; 34% of which was incurred in the first two months of FY 2015 alone.</p><p>The analysis found that the largest category of work for the FDA has been in performing the investigational new drug application (IND) and pre-IND work for the biosimilars, including the BPD meetings &ndash; 55.8 FTEs and 89,276.53 hours.</p><p>The FDA reported it had 32 meeting requests in FY 2013, which grew to 54 in FY 2014 &ndash; a 69% increase.</p><p>In the first two quarters of FY 2015, there were 27 meeting requests.</p><p>The number of scheduled meetings also increased 57% during the second year of the biosimilar program, from 30 to 47. </p><p>There were 35 scheduled meetings in the first two quarters of FY 2015.</p><p>At the Sept. 17 hearing, Woodcock noted in testimony that as biosimilar development programs mature, "the type of interaction with FDA is changing" &ndash; with companies shifting now to requesting more of the BPD "Type 2" meetings, where they can discuss a specific issue, like a proposed study design or endpoints, and ask questions where regulators can provide targeted advice.</p><p>The Type 2 meetings can include substantive review of summary data, but do not include review of full study reports. </p><p>ERG reported that biosimilars policy work ranked second behind IND and pre-IND activities at the FDA, with 23.7 FTEs and 37,906.1 hours.</p><p>Science and research work was the third largest category, with 21 FTEs and 33,592.33 hours.</p><p>Because the FDA had only been performing 351(k) reviews since the middle of FY 2014, ERG noted that process only accounted for 12.8 FTEs.</p><p>The FDA is required under BsUFA to publish a final report on workload volume and costs by September of 2016, which ERG said will expand on and update the interim analysis and fill in the gaps in the initial evaluation's estimates, including data on the time spent on clinical inspections, which the company said was "lacking," and postmarketing work, which was not available, given Zarxio only entered the market on <a href="http://www.scripintelligence.com/home/1st-U.S.-Biosimilar-Arrives-Zarxio-Launches-Legal-Saga-Ongoing-360244" target="_new">Sept. 3</a>.</p><p>Regulators said the Dec. 18 meeting, in which attendees are required to <a href="https://fdapublicmeeting-bsufa.eventbrite.com" target="_new">register by Nov. 18</a>, likely will include presentations by the FDA and a series of panels representing different stakeholder groups. </p><p>The agency said there also will be an opportunity at the meeting for other stakeholders to provide public comments, which the FDA said should focus on process enhancements and funding, but not on policy issues, since the latter are "beyond the scope" of the BsUFA reauthorization discussions.</p><p>Nonetheless, it's likely issues like pending guidances, such as interchangeability, will be raised at the meeting by stakeholders if the documents are not yet out by the time the meeting rolls around.</p><p>But at the Sept. 17 Senate hearing, the FDA's Woodcock made it clear the agency was more focused on <a href="http://www.scripintelligence.com/home/Woodcock-FDA-Focused-On-Biosimilars-Science-Before-Policy-360510" target="_new">getting the science right</a> before dealing with policy matters, such as completing guidances.</p><p><b>In other Washington news:</b></p><p><a href="http://www.scripintelligence.com/home/Odds-On-Favorite-Ubl-Confirmed-As-Next-PhRMA-CEO-360696" target="_new">Odds-On-Favorite Ubl Confirmed As Next PhRMA CEO</a></p><p>The Pharmaceutical Research and Manufacturers of America late on Sept. 25 confirmed what had been widely speculated about in Washington and among industry insiders that AdvaMed CEO Stephen Ubl would be taking the reins as the next chief of the drug lobbying group.</p><p><a href="http://www.scripintelligence.com/home/Turings-Shkreli-Caves-To-Pressure-Lowering-Daraprim-Price-360631" target="_new">Turing's Shkreli Caves To Pressure; Lowering Daraprim Price</a></p><p>Martin Shkreli, the hedge funder-turned-pharma CEO, who jacked up the price of a rare disease medicine from $13.50 to $750 per pill after acquiring it last month, found out the hard way that picking a fight with the HIV/AIDS advocacy community and presidential candidates already on the war path about skyrocketing drug prices wasn't the best idea.</p><p><a href="http://www.scripintelligence.com/home/Biotech-Walloped-On-Clinton-Drug-Price-Controls-Threat-360599" target="_new">Biotech Walloped On Clinton Drug Price Controls Threat</a></p><p>It was d√©j&agrave; vu all over again on Wall Street on Sept. 21 when biotech stocks took a beating after a powerful Washington politician vowed to take action to control prescription drug prices &ndash; a whipping reminiscent of March 2014 after three Democratic lawmakers set off a frenzy by suggesting they may pursue a similar path when they called on Gilead Sciences to explain its $1,000-per-pill price for its hepatitis C virus medicine Sovaldi (sofosbuvir).</p><p><a href="http://www.scripintelligence.com/home/Amgen-Covering-Its-Bases-In-Hospira-Biosimilars-Suit-360602" target="_new">Amgen Covering Its Bases In Hospira Biosimilars Suit</a></p><p>Seeking to obtain more clarity on the interpretation of the <i>Biologics Price Competition and Innovation Act</i>, Amgen Inc. has filed another lawsuit involving a biosimilar of one of its products &ndash; this time Epogen (epoetin alfa), the firm's first FDA-approved therapeutic, which gained the agency's blessing in 1989.</p><p><a href="http://www.scripintelligence.com/home/No-Patent-Board-Sanctions-For-Bass-Celgene-Denied-360697" target="_new">No Patent Board Sanctions For Bass; Celgene Denied</a></p><p>Celgene failed to convince the U.S. Patent & Trademark Office's Patent Trial and Appeal Board to impose sanctions against hedge fund manager Kyle Bass and dismiss his inter partes review petitions on the grounds of abuse of process and improper use of the proceedings.</p><p><a href="http://#http://www.scripintelligence.com/home/Novo-Diabetes-Drugs-Tresiba-Ryzodeg-OKd-Pressures-Sanofi-360695" target="_new">Novo Diabetes Drugs Tresiba, Ryzodeg OK'd; Pressures Sanofi</a></p><p>Watch out Sanofi. Danish drug maker Novo Nordisk just won the FDA's approval for two new long-acting insulins &ndash; Tresiba (insulin degludec injection) and Ryzodeg (insulin degludec/insulin aspart injection), which will be marketed as therapies to improve glycemic control in patients with types I and II diabetes.</p><p><a href="http://www.scripintelligence.com/home/Shutdown-Looms-Another-FDA-Merry-go-round-Ride-360647" target="_new">Shutdown Looms: Another FDA Merry-go-round Ride</a></p><p>The FDA has been on this merry-go-round before: If Congress doesn't act by Oct. 1 to pass a fiscal year 2016 budget &ndash; or at least a short-term or long-term continuing resolution &ndash; the federal government will shut down, which means the agency would be forced to close its doors, potentially stalling new drug and biologic applications and putting off other work vital to the biopharmaceutical industry.</p><p><a href="http://www.scripintelligence.com/home/Device-Lobbyist-Ubl-Rumored-To-Take-PhRMA-Helm-360651" target="_new">Device Lobbyist Ubl Rumored To Take PhRMA Helm</a></p><p>With Pharmaceutical Research and Manufacturers of AmericaCEO John Castellani soon departing, bets in Washington were on medical device lobbyist Stephen J. Ubl to take the drug group's helm in the next few months.</p><p><a href="http://www.scripintelligence.com/policyregulation/CTI-BioPharma-Plans-Q4-Pacritinib-NDA-Accelerated-OK-360650" target="_new">CTI BioPharma Plans Q4 Pacritinib NDA, Accelerated OK</a></p><p>Shares of CTI BioPharma rose nearly 12% on Sept. 23 after the company said it plans to submit a new drug application in the fourth-quarter for pacritinib following a "productive" meeting with the FDA.</p><p><a href="http://www.scripintelligence.com/home/U.S.-Government-Shutdown-Threatens-Research-Patients-360630" target="_new">U.S. Government Shutdown Threatens Research, Patients</a></p><p>With the clock ticking on the end of the current fiscal year, Congress' calendar, Dr. Francis Collins, director of the National Institutes of Health, and Rep. Chris Van Hollen (D-MD), ranking member on the House Budget Committee, on Sept. 22 tried to put a human face on the toll another shutdown of U.S. federal agencies would take if lawmakers let an ideological dispute stand in the way of funding the government.</p><p><a href="http://www.scripintelligence.com/policyregulation/Regeneron-Nabs-BARDA-Ebola-Antibodies-Cocktail-Deal-360604" target="_new">Regeneron Nabs BARDA Ebola Antibodies Cocktail Deal</a></p><p>The U.S. Biomedical Advanced Research and Development Authority awarded Regeneron Pharmaceuticals Inc. $17m to develop, test and manufacture a monoclonal antibody therapy to treat Ebola under an agreement in which the company could garner an additional $21m to test the product in a Phase I trial.</p><p>This and past US Capitol Capsule columns are available at <a href="http://www.scripintelligence.com/capitolcapsule/" target="_new">http://www.scripintelligence.com/capitolcapsule/</a></p><p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 474

<p>As the FDA gets ready to embark on the reauthorization process for the next round of the <i>Biosimilar User Fee Act </i>(BsUFA), which permits the agency to collect user fees from industry to aid in the reviews of biosimilars applications, known as 351(k)s, it wants to hear stakeholders' thoughts at a Dec. 18 public meeting on how well regulators are completing their program goals so far and what should be retained, changed or discontinued to improve performance.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 72

US Capitol Capsule Improving The Biosimilars Review Process Whats Needed
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150922T120000
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150922T120000
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150922T120000
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029886
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 76

US Capitol Capsule: Improving The Biosimilars Review Process: What's Needed?
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

headline news
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360608
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042456Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

5d3976ba-1c55-40de-a1ad-666f1e67380e
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042456Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
